Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma – a retrospective evaluation

Bone Marrow Transplantation volume 34, pages 781–786 (2004)Cite this article

Summary:

The purpose of this evaluation was to investigate the efficacy of high-dose chemotherapy with thiotepa, melphalan, and carboplatin (TMCb), and of autologous peripheral blood stem cell (PBSC) infusion in patients with aggressive non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD). A total of 42 patients, 23 with intermediate-grade NHL and 19 with HD, received thiotepa (500 mg/m2), melphalan (100 mg/m2), and carboplatin (1050–1350 mg/m2) followed by autologous PBSC infusion. Of 21 patients with more advanced disease, four had primary refractory disease, one was in complete remission (CR)-2, 11 were in first refractory relapse, and five were beyond first relapse. Of 21 patients with less advanced disease, two were in CR-1, four were in CR-2, and 15 were in first responding relapse. In all, 14 patients (33%) had received prior radiotherapy prohibiting a total-body irradiation (TBI)-based conditioning regimen. The projected 2-year probabilities of survival, event-free survival (EFS), and relapse for all patients were 0.65, 0.60, and 0.21 (0.85, 0.80, and 0.10 for patients with less advanced disease and 0.47, 0.42, and 0.33 for patients with more advanced disease). The probability of nonrelapse mortality in the first 100 days was 0.12. Grade 3–4 regimen-related toxicities (RRT) occured in five of 42 (12%) patients and death due to grade-4 RRT occured in only one (2.5%) patient. These preliminary data suggest that 0.42% EFS in this study for advanced disease patients is highly encouraging and high-dose TMCb followed by autologous PBSC transplantation is well tolerated as well as an effective regimen in patients with intermediate-grade NHL or HD, and may be comparable to some previously used regimens including TBI-based regimens.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Sarosy G, Leyland-Jones B, Soochan P et al. The systemic administration of intravenous melphalan. J Clin Oncol 1988; 6: 1768–1782.

    Article  CAS  PubMed  Google Scholar 

  2. Wright JC, Golomb FM, Gumport SL et al. Summary of results with triethylenethiophosphoramide. Ann NY Acad Sci 1958; 68: 937–966.

    Article  CAS  PubMed  Google Scholar 

  3. Schiffman K, Buckner CD, Maziarz R et al. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. Biol Blood Marrow Transplant 1997; 3: 261–266.

    CAS  PubMed  Google Scholar 

  4. Shea TC, Flaherty M, Elias A et al. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 1989; 7: 651–655.

    Article  CAS  PubMed  Google Scholar 

  5. Demirer T, Ilhan O, Mandel NM et al. A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies. Bone Marrow Transplant 2000; 25: 697–703.

    Article  CAS  PubMed  Google Scholar 

  6. Demirer T, Uysal VA, Ayli M et al. High-dose thiotepa, melphalan, and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer – a retrospective evaluation. Bone Marrow Transplant 2003; 31: 755–761.

    Article  CAS  PubMed  Google Scholar 

  7. Hill R . The Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Instıtute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112–2117.

    Article  Google Scholar 

  8. Lukes RJ, Butler JJ . The pathology and nomenclature of Hodgkin's disease. Cancer Res 1966; 26: 1063–1070.

    CAS  PubMed  Google Scholar 

  9. Weaver CH, Petersen FB, Appelbaum FR et al. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem cell support in patients with malignant lymphoma. J Clin Oncol 1994; 12: 2559–2566.

    Article  CAS  PubMed  Google Scholar 

  10. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562–1568.

    Article  CAS  PubMed  Google Scholar 

  11. Shubart MC, McDonald GB . Gastrointestinal and hepatic complications. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific Publications: Massachusetts, USA, 1994; pp 454–459.

    Google Scholar 

  12. Crawford SW . Critical care and respiratory failure. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific Publications: Massachusetts, USA, 1994; pp 513–517.

    Google Scholar 

  13. Demirer T, Aylı M, Ozcan M et al. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte-colony stimulating factor (Rh-GSCF): a randomized evaluation of different doses of Rh-GSCF. Br J Haematol 2002; 116: 468–472.

    Article  CAS  PubMed  Google Scholar 

  14. Demirer T, Aylı M, Daglı M et al. Influence of post-transplant recombinant human granulocyte-colony stimulating factor administration on peritransplant morbidity in patients undergoing autologous stem cell transplantation. Br J Haematol 2002; 118: 1104–1111.

    Article  CAS  PubMed  Google Scholar 

  15. Demirer T, lhan O, Aylı M et al. Monitoring of peripheral blood CD34+ cell counts on the first day of apheresis is highly predictive for efficient CD34+ cell yield. Therap Apheresis 2002; 6: 384–389.

    Article  Google Scholar 

  16. Rowley SD, Bensinger WI, Gooley T et al. Effect of cell concentration on bone marrow and peripheral blood stem cell cryopreservation. Blood 1994; 83: 2731–2736.

    CAS  PubMed  Google Scholar 

  17. Demirer T, Dagl M, Ilhan O et al. A randomized trial of assessment of efficacy of leukapheresis volumes, 8 l vs 12 l. Bone Marrow Transplant 2002; 29: 893–897.

    Article  CAS  PubMed  Google Scholar 

  18. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral blood stem cells. J Clin Oncol 1995; 13: 2547–2555.

    Article  CAS  PubMed  Google Scholar 

  19. Gorin NC . Stem cell processing and transplantation. The present models of acute leukemias and non-hodgkin's lymphomas in adults. Turkish J Hematol 1996; 14: 15–21.

    Google Scholar 

  20. Press OW, Livingston R, Mortimer J et al. Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. J Clin Oncol 1991; 9: 423–432.

    Article  CAS  PubMed  Google Scholar 

  21. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  22. Appelbaum FR, Sullivan KM, Buckner CD et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total-body irradiation, and marrow transplantation. J Clin Oncol 1987; 5: 1340–1347.

    Article  CAS  PubMed  Google Scholar 

  23. Petersen FB, Appelbaum FR, Bigelow CL et al. High-dose cytosine arabinoside, total-body irradiation and marrow transplantation for advanced malignant lymphoma. Bone Marrow transplant 1989; 4: 483–488.

    CAS  PubMed  Google Scholar 

  24. Gutierrez-Delgado F, Holmberg L, Hooper H et al. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan, and thiotepa compared to a radiation-based regimen. Bone Marrow Transplant 2003; 32: 279–285.

    Article  CAS  PubMed  Google Scholar 

  25. Weaver CH, Appelbaum FR, Petersen FB et al. High-dose cyclophosphamide, carmustine and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. J Clin Oncol 1993; 11: 1329–1335.

    Article  CAS  PubMed  Google Scholar 

  26. Gulati S, Yahalom J, Acaba K et al. Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total-body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation. J Clin Oncol 1992; 10: 936–941.

    Article  CAS  PubMed  Google Scholar 

  27. Srivastava A, Bradstock KF, Szer J et al. Busulfan and melphalan prior to autologous bone marrow transplantation. Bone Marrow Transplant 1993; 12: 323–329.

    CAS  PubMed  Google Scholar 

  28. Goldstone AH, McMillan AK, Chopra R et al. High-dose therapy for the treatment of non-Hodgkin's lymphoma. In: Armitage JO, Antman KH (eds). High-Dose Cancer Therapy; Pharmacology, Hematopoietins, Stem Cells. Williams & Wilkins: Baltimore, MD, 1992; pp 662–676.

    Google Scholar 

  29. Crump M, Smith AM, Brandwein J et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: Importance of disease status at transplant. J Clin Oncol 1993; 11: 711–740.

    Article  Google Scholar 

  30. Wheeler C, Antin JH, Churchill M et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol 1990; 8: 648–654.

    Article  CAS  PubMed  Google Scholar 

  31. Horning SJ, Negrin RS, Chao NJ et al. High-dose etoposide regimens and autologous bone marrow transplantation (ABMT) for malignant lymphoma: results in 202 consecutive patients. Proc ASCO (abstract) 1993; 12: 382.

    Google Scholar 

  32. Stockerl-Goldstein KE, Horning SF, Negrin RS et al. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 1996; 2: 76–81.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology/Oncology, Ankara University Medical School, Ankara, Turkey

    T Demirer, M Ozcan, M Arat, O Arslan, G Gurman, H Akan & O Ilhan

  2. Department of Bone Marrow Transplantation Unit, Ankara Numune Education and Research Hospital, Ankara, Turkey

    M Ayli

  3. Department of Medical Oncolgy, Ankara Oncology Hospital, Ankara, Turkey

    T Fen

  4. Department of Medical Oncolgy, Gaziantep University Medical School, Ankara, Turkey

    S Buyukberber

Authors
  1. T Demirer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Ayli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Fen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Ozcan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Arat
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Buyukberber
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. O Arslan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G Gurman
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H Akan
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. O Ilhan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T Demirer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Demirer, T., Ayli, M., Fen, T. et al. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma – a retrospective evaluation. Bone Marrow Transplant 34, 781–786 (2004). https://doi.org/10.1038/sj.bmt.1704672

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704672

Keywords

This article is cited by

Search

Advanced search

Quick links